文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

以抗生素和液体为核心的集束化治疗可能改善脓毒症管理,但缺乏高质量证据支持SEP-1所要求的特异性

Antibiotic- and Fluid-Focused Bundles Potentially Improve Sepsis Management, but High-Quality Evidence Is Lacking for the Specificity Required in the Centers for Medicare and Medicaid Service's Sepsis Bundle (SEP-1).
PubMed 文献 · Crit Care Med · 2019-01-01
一句话结论观察性研究提示以抗生素和液体为核心的脓毒症集束化治疗与生存改善相关,但无高质量证据支持SEP-1中3小时内抗生素、30 mL/kg液体或6小时内重复乳酸测定的具体规定。

该Meta分析纳入17项观察性研究(11,303例对照和4,977例集束化治疗患者),评估以抗生素和液体为核心的脓毒症集束化治疗与生存的关系。集束化治疗与生存 odds 增加相关(OR 1.20-2.03),但异质性显著(I²=61%),且仅在 largest 和 medium-sized 研究中一致。抗生素时机(1小时 vs 3小时 vs 未指定)和液体量(30 mL/kg vs 其他)的比较均无显著差异(p=0.19)。唯一采用连续乳酸测定的研究未显示生存获益。无研究为低偏倚风险或评估不良事件。作者认为现有证据支持修订SEP-1,允许根据医生判断灵活治疗。

要点

  • 17项观察性研究(11,303例对照和4,977例集束化治疗患者)显示,脓毒症集束化治疗与生存 odds 增加相关(OR 1.20-2.03),但异质性显著(I²=61%)。
  • 五个最大研究(每项1,697-12,486例)中生存获益一致(OR 1.20 [95%CI 1.11-1.30];I²=0%),六个中等研究(167-1,029例)OR 2.03 [1.52-2.71];六个最小研究(64-137例)OR 1.25 [0.42-3.66],未达统计学显著。
  • 抗生素时机(1小时 vs 3小时 vs 未指定)和液体量(30 mL/kg vs 其他)的比较均无显著差异(p=0.19)。
  • 唯一采用连续乳酸测定的研究未显示生存获益。
  • 无研究为低偏倚风险或评估集束化治疗的不良事件;作者认为现有证据支持修订SEP-1,允许根据医生判断灵活治疗。

适用人群与场景

  • 脓毒症成人患者(研究比较接受与未接受以抗生素和液体为核心的集束化治疗者的生存)。

研究设计与关键结果

  • 研究类型:Meta分析,纳入17项观察性研究,共11,303例对照和4,977例集束化治疗患者。
  • 主要终点:集束化治疗与生存 odds 增加相关(15项研究,OR 1.20-2.03),但异质性显著(I²=61%;p<0.01)。
  • 五个最大研究(每项1,697-12,486例)中生存获益一致(OR 1.20 [95%CI 1.11-1.30];I²=0%)。
  • 六个中等研究(167-1,029例)中OR 2.03 [95%CI 1.52-2.71];I²=8%。
  • 六个最小研究(64-137例)中OR 1.25 [95%CI 0.42-3.66];I²=57%,未达统计学显著。
  • 抗生素时机比较:要求1小时内(7项研究)vs 3小时内(8项研究)vs 未指定时间(2项研究),生存获益相似(p=0.19)。
  • 液体量比较:30 mL/kg(7项研究)vs 其他容量(≥2 L,1项;≥20 mL/kg,2项;1.5-2 L或500 mL各1项;未指定4项),生存获益相似(p=0.19)。
  • 唯一采用连续乳酸测定的研究未显示生存获益。

证据类型、等级与局限

  • 证据类型:Meta分析,纳入17项观察性研究。
  • 无研究为低偏倚风险。
  • 异质性显著(I²=61%;p<0.01)。
  • 无研究评估集束化治疗的潜在不良效应。

对床旁实践的改变

  • 作者认为,现有研究支持以抗生素和液体为核心的脓毒症集束化治疗(如SEP-1)改善生存,但未证明任何特定抗生素时机、液体量或连续乳酸测定的优越性。
  • 作者认为,在强有力可重复证据证明任何固定要求的安全性和获益之前,现有发现支持修订SEP-1,允许根据医生判断灵活治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To address three controversial components in the Centers for Medicare and Medicaid Service's sepsis bundle for performance measure (SEP-1): antibiotics within 3 hours, a 30 mL/kg fluid infusion for all hypotensive patients, and repeat lactate measurements within 6 hours if initially elevated. We hypothesized that antibiotic- and fluid-focused bundles like SEP-1 would probably show benefit, but evidence supporting specific antibiotic timing, fluid dosing, or serial lactate requirements would not be concordant. Therefore, we performed a meta-analysis of studies of sepsis bundles like SEP-1.

DATA SOURCES: PubMed, Embase, ClinicalTrials.gov through March 15, 2018.

STUDY SELECTION: Studies comparing survival in septic adults receiving versus not receiving antibiotic- and fluid-focused bundles.

DATA EXTRACTION: Two investigators (D.J.P., P.Q.E.).

DATA SYNTHESIS: Seventeen observational studies (11,303 controls and 4,977 bundle subjects) met inclusion criteria. Bundles were associated with increased odds ratios of survival (odds ratio [95% CI]) in 15 studies with substantial heterogeneity (I = 61%; p < 0.01). Survival benefits were consistent in the five largest (1,697-12,486 patients per study) (1.20 [1.11-1.30]; I = 0%) and six medium-sized studies (167-1,029) (2.03 [1.52-2.71]; I = 8%) but not the six smallest (64-137) (1.25 [0.42-3.66]; I = 57%). Bundles were associated with similarly increased survival benefits whether requiring antibiotics within 1 hour (n = 7 studies) versus 3 hours (n = 8) versus no specified time (n = 2); or 30 mL/kg fluid (n = 7) versus another volume (≥ 2 L, n = 1; ≥ 20 mL/kg, n = 2; 1.5-2 L or 500 mL, n = 1 each; none specified, n = 4) (p = 0.19 for each comparison). In the only study employing serial lactate measurements, survival was not increased versus others. No study had a low risk of bias or assessed potential adverse bundle effects.

CONCLUSIONS: Available studies support the notion that antibiotic- and fluid-focused sepsis bundles like SEP-1 improve survival but do not demonstrate the superiority of any specific antibiotic time or fluid volume or of serial lactate measurements. Until strong reproducible evidence demonstrates the safety and benefit of any fixed requirement for these interventions, the present findings support the revision of SEP-1 to allow flexibility in treatment according to physician judgment.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Pepper DJ, Sun J, Cui X, et al. Antibiotic- and Fluid-Focused Bundles Potentially Improve Sepsis Management, but High-Quality Evidence Is Lacking for the Specificity Required in the Centers for Medicare and Medicaid Service's Sepsis Bundle (SEP-1). Crit Care Med. 2019. PMID: 31369426. doi:10.1097/CCM.0000000000003892

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。